Teva Gets Funding to Close Allergan Deal With Franc Bond Sale

Teva Pharmaceutical Industries Ltd. sold Swiss-franc denominated bonds and said it had raised enough money in a sweep of markets worldwide to close a $40.5 billion acquisition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.